Japan’s success in curbing COVID-19 cases now hampers search for cures By Reuters

© Reuters.  Office workers wearing protective face masks walk to head home at sunset amid the coronavirus disease (COVID-19) outbreak, in Tokyo

By Rocky Swift

TOKYO (Reuters) – As nations race to develop treatments and vaccines for COVID-19, Japan has become a victim of its own success as slowing new infections has led to a shortage of patients to enroll in clinical trials.

Clinical trials are underway for more than a dozen potential vaccines, including at least six in China, but Japan’s first human trials are expected to start next month.

In development of treatments, Russia and India approved Fujifilm Holdings Corp’s (T:) Avigan as a COVID-19 therapy, but Japan, whose Prime Minister Shinzo Abe has touted the drug’s potential and hoped to approve it in May, won’t see a decision until at least July.

“Due to the decreasing number of coronavirus infections, we believe it will take some time

Read More

Stocks are gaining this morning after Trump reassures investors China deal ‘fully intact’

U.S. stocks rose for a second day ahead of data that’s expected to show the economy extended its recovery from the virus-induced contraction. Treasuries and the dollar retreated.

The S&P 500 pushed to a two-week high with investors continuing to focus on signs the American economy is bouncing back from the shutdown. Investors remain on edge over tension with China after a wild overnight session that saw futures plunge after a White House adviser said the trade deal was over. They rebounded when after President Donald Trump contradicted the statement.

The Dow Jones Industrial Average rose 134.43 points, or 0.52 per cent, at the open to 26,159.39. The S&P 500 opened higher by 20.84 points, or 0.67 per cent, at 3,138.70. The Nasdaq Composite gained 74.35 points, or 0.74 per cent, to 10,130.83 at the opening bell. The Toronto Stock Exchange’s S&P/TSX composite index was up 147.06 points, or 0.95

Read More

One of the world’s richest families is fighting over a letter dividing their $11.2 billion fortune

© 2020 Fortune Media IP Limited. All Rights Reserved. Use of this site constitutes acceptance of our Terms of Use and Privacy Policy (Your California Privacy Rights) | CCPA Do Not Sell My Information | Ad Choices 
FORTUNE is a trademark of Fortune Media IP Limited, registered in the U.S. and other countries. FORTUNE may receive compensation for some links to products and services on this website. Offers may be subject to change without notice.
Quotes delayed at least 15 minutes. Market data provided by Interactive Data. ETF and Mutual Fund data provided by Morningstar, Inc. Dow Jones Terms & Conditions: http://www.djindexes.com/mdsidx/html/tandc/indexestandcs.html.
S&P Index data is the property of Chicago Mercantile Exchange Inc. and its licensors. All rights reserved. Terms & Conditions. Powered and implemented by Interactive Data Managed Solutions. | EU Data Subject Requests

Read More